Immune checkpoint inhibitors target specific pathways such as CTLA4 and PD-1, and have shown remarkable success against melanoma [4], non-small-cell lung cancer [5], and Hodgkin’s lymphoma [6], with mixed results in several other cancers. Here, CTLA4 is linked to cancer.